Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer.
Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer.
复制标题
靶向 NLRP3 炎症小体作为克服癌症的新治疗选择。
DOI：
10.3390/cancers13102297
复制
发表时间：
2021-05-11
期刊：
影响因子：
5.2
通讯作者：
Giorgi C
中科院分区：
文献类型：
--
作者：
Missiroli S;Perrone M;Boncompagni C;Borghi C;Campagnaro A;Marchetti F;Anania G;Greco P;Fiorica F;Pinton P;Giorgi C
NLRP3 炎症小体是一种细胞质多蛋白复合物，可响应细胞应激而进行组装，并促进炎症细胞因子白细胞介素 1β 和 IL-18 的成熟和释放，从而促进免疫反应和炎症。异常的 NLRP3 激活在癌症等炎症相关疾病的发病机制中具有不同的作用，因为它可以以上下文依赖性和组织特异性的方式同时具有促肿瘤和抗肿瘤作用。因此，通过抑制剂、拮抗剂和单克隆抗体等多种药物对癌细胞中的 NLRP3 炎症小体进行微调，已被认为是一种可行的癌症治疗方法。炎症小体是多蛋白复合物，调节促炎细胞因子白细胞介素-1β（IL-1β和白细胞介素-18（IL-18）的成熟和分泌，以响应各种细胞内刺激。作为炎症小体家族的一员，NLRP3是研究最多、特征最清楚的炎症小体，并已被证明参与多种病理学。最近的研究结果表明，NLRP3炎症小体也可能参与多种病理学过程。在肿瘤发生中发挥着核心作用，它作为潜在的抗癌治疗靶点而受到关注。在这篇综述中，我们讨论了 NLRP3 在癌症发生和进展中的作用，详细总结了 NLRP3 炎症小体激活（和抑制）在各种类型癌症的发病机制中的作用。此外，我们重点关注了靶向 NLRP3 的癌症治疗潜力，强调了解 NLRP3 炎症小体依赖性癌症机制如何指导靶向该肿瘤的新药的开发。肿瘤相关细胞的炎症反应。
NLRP3 inflammasome is a cytoplasmic multiprotein complex that assembles in response to cellular distress and promotes maturation and release of the inflammatory cytokines interleukin-1β and IL-18, which contribute to immune responses and inflammation. Aberrant NLRP3 activation has divergent roles in the pathogenesis of inflammation-associated diseases such as cancer, as it can have both protumorigenic and antitumorigenic effects in a context-dependent and tissue-specific manner. Therefore, the fine-tuning of the NLRP3 inflammasome in cancer cells, through a wide range of agents including, such as inhibitors, antagonists and monoclonal antibodies, has been suggested as a viable approach to cancer therapy. Inflammasomes are multiprotein complexes that regulate the maturation and secretion of the proinflammatory cytokines interleukin-1beta (IL-1β and interleukin-18 (IL-18) in response to various intracellular stimuli. As a member of the inflammasomes family, NLRP3 is the most studied and best characterized inflammasome and has been shown to be involved in several pathologies. Recent findings have made it increasingly apparent that the NLRP3 inflammasome may also play a central role in tumorigenesis, and it has attracted attention as a potential anticancer therapy target. In this review, we discuss the role of NLRP3 in the development and progression of cancer, offering a detailed summary of NLRP3 inflammasome activation (and inhibition) in the pathogenesis of various forms of cancer. Moreover, we focus on the therapeutic potential of targeting NLRP3 for cancer therapy, emphasizing how understanding NLRP3 inflammasome-dependent cancer mechanisms might guide the development of new drugs that target the inflammatory response of tumor-associated cells.
登录
查看更多内容
DOI：
10.1084/jem.20161707
发表时间：
2017-06-05
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Daley D;Mani VR;Mohan N;Akkad N;Pandian GSDB;Savadkar S;Lee KB;Torres-Hernandez A;Aykut B;Diskin B;Wang W;Farooq MS;Mahmud AI;Werba G;Morales EJ;Lall S;Wadowski BJ;Rubin AG;Berman ME;Narayanan R;Hundeyin M;Miller G
通讯作者：
Miller G
影响因子：
24.5
作者：
Bauer, Christian;Duewell, Peter;Schnurr, Max
通讯作者：
Schnurr, Max
DOI：
10.1084/jem.20100050
发表时间：
2010-05-10
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Allen IC;TeKippe EM;Woodford RM;Uronis JM;Holl EK;Rogers AB;Herfarth HH;Jobin C;Ting JP
通讯作者：
Ting JP
影响因子：
1.3
作者：
de Castro-Sobrinho, Jucara Maria;Rabelo-Santos, Silvia Helena;Zeferino, Luiz Carlos
通讯作者：
Zeferino, Luiz Carlos
影响因子：
--
作者：
Chang CM;Wang ML;Lu KH;Yang YP;Juang CM;Wang PH;Hsu RJ;Yu MH;Chang CC
通讯作者：
Chang CC